FDA Decision Due on Vanda Pharma's Gastroparesis Drug
By Colin Kellaher
A Food and Drug Administration decision is due this week on a proposed drug from Vanda Pharmaceuticals to treat gastroparesis, a condition that affects the stomach muscles and prevents proper stomach emptying.
The FDA in December 2023 accepted Vanda's application seeking approval of tradipitant for the treatment of symptoms of the digestive condition, and the agency set a target action date of Sept. 18.
Vanda has previously said that an FDA green light would make tradipitant the first novel drug approved by the agency in more than four decades for gastroparesis, but in its second-quarter financial report in late July, Vanda disclosed that the FDA had provided a preliminary notice that deficiencies were precluding the discussion of labeling.
Vanda in April 2012 inked a license agreement with Eli Lilly to develop and commercialize tradipitant for all human indications. Eli Lilly is due a $10 million milestone for the first U.S. approval for tradipitant.
Vanda earlier this year reported positive results from a second Phase 3 study of tradipitant for the treatment of motion sickness and said it planned to file for FDA approval by the end of the year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 18, 2024 06:58 ET (10:58 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying